Technology Innovation Intelligence SAAS Track Unicorn Smart Ba Since the new drug intelligence library product was officially launched in March 2022, the number of users of this product has continued to rise worldwide, and the production and research team has received high-quality constructive opinions from many users to help the product iterate quickly. The current NPS value has reached 9.38 points.
To thank all users, Zhihuiya New Drug Intelligence Product has launched a report module, aiming to meet the vast majority of the non-standard search needs of millions of potential professional users around the world in the process of using data retrieval. This section has joined hands with 
0 experts from world-renowned pharmaceutical companies, first-line biomedical investment institutions and biomedical professional consulting service providers to publish , 40+ , the Chinese and English version reports of six major topics such as , , 40+ The premium industry report has been launched on the Smart Yao New Drug Intelligence Library mini program and web terminal. More than 100 reports will be released in the next three months, and all users can try it for free. If the user completes daily tasks in the corresponding mini program, he or she can read and download all the reports that have been put on the shelves for free.
Series 1: Drug Research Report
On October 21, 2022, the Smart Ya New Drug Intelligence Library officially released the Smart Ya Biomedical Series Drug Report (hereinafter referred to as the "Report"). This series of reports selects new and good drugs worthy of attention worldwide, conducts multi-dimensional research, and provides detailed introductions to drug information, drug description, pharmacology , toxicology , clinical research, global approval and marketing status, global patent layout , global market and competition situation, and analysis of and other information, helping readers quickly grasp the full picture of drug information. Taking the Tirzepatide drug report as an example, the report takes Tirzepatide as the research object and comprehensively reports its basic drug information, global marketing status, existing and subsequent clinical research worthy of attention, and conducts detailed research on its global patent layout, global market and competition.
The series of reports will be launched in the next month. Time preview of the Smart Ba New Drug Intelligence Library:
Series 2: Drug Delivery Series Report
Starting from July 1, 2022, MedBioCapital (MidBai Capital) and Smart Ba New Drug Library officially released the drug delivery series industry research report . A total of 5 Chinese reports have been released in this series of reports. The corresponding English version report will also be launched in the near future.
Series 3: Patent Analysis Report
Online Preview:
Patent Analysis Report: "ATM Inhibitor Patent Research Report in the Field of Synthetic Lethality" is expected to be launched on 2022/11/14/2022
Series 4: Special Report on the Research and Development Scenario of New Drugs for Application of AI Technology
Series 5: Industry Insight Report
Series 6: Global Drug R&D Progress
Since early March 2022, the Smart Ba New Drug Intelligence Library has regularly released the " Global Drug R&D Progress Monthly Report " before every 10 days. The report series has been read and downloaded so far.
Knowledge Copyright Statement: The copyright of this report is owned by Zhihuiya. It may not be reproduced, excerpted or used in other ways without Zhihuiya’s authorization. If authorized, it should be used within the scope of authorization and indicate the source. Those who violate the above statement will be held accountable for relevant legal liability.
